Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)
SANDOZ CANADA INCORPORATED
L01XG01
BORTEZOMIB
3.5MG
POWDER FOR SOLUTION
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER) 3.5MG
INTRAVENOUS
SC: 1.4ML / I.V: 3.5ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0150433001; AHFS:
CANCELLED PRE MARKET
2021-04-21
_Bortezomib for Injection _ _Page 1 of 75_ PRODUCT MONOGRAPH Pr BORTEZOMIB ® FOR INJECTION 3.5 mg/vial bortezomib, as mannitol boronic ester Sterile lyophilized powder Antineoplastic Agent Sandoz Canada Inc. 110 rue de Lauzon Boucherville, Québec, Canada J4B 1E6 Date of Revision: February 15, 2019 Submission Control No: 224415 _Bortezomib for Injection _ _Page 2 of 75_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................. 11 DRUG INTERACTIONS ................................................................................................. 29 DOSAGE AND ADMINISTRATION ............................................................................. 30 OVERDOSAGE ................................................................................................................ 37 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 37 STORAGE AND STABILITY ......................................................................................... 39 SPECIAL HANDLING INSTRUCTIONS ....................................................................... 39 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 39 PART II: SCIENTIFIC INFORMATION .............................................................................. 40 PHARMACEUTICAL INFORMATION ......................................................................... 40 CLINICAL TRIALS .... Přečtěte si celý dokument